An integrated launch plan was just the start for helping to transform a research organization into a commercial entity. A successful commercial launch of an FDA-approved specialty drug included project management support to a cross-functional client team and development of a dashboard tool to track each function’s progress.
Collaborative helped a research company transitioning to commercialization identify critical timelines, tasks, milestones and resources required to bring a new drug to market. As part of the project, leaders were given the information and tools they needed and the business began building the strong foundation necessary for a successful launch.
Commercial launch is a critical and complex period in the Life Sciences product life cycle. The transition from clinical development to commercial operations can seem overwhelming as companies face considerable challenges in transforming from an R&D-driven organization to one focused on achieving in-market business and commercial excellence. Core to successful launches is preparing the company for a whole new raft of capabilities, processes, and relationships, and in doing so there are a number of factors included in this checklist that companies should consider and questions they should answer.
Top 5 Factors Every Bio-Tech and Pharmaceutical Company Must Keep in Mind.
Successfully launching a product in the U.S. requires a balance across commercial strategy, government programs, and contracting operations. While the market holds significant opportunity, there are also complexities that need to be considered prior to launch.
To prepare for the launch of your drug in the U.S. market, download a copy of Navigating the U.S. Government Market to help your organization remain compliant with government operational and pricing requirements.
Published By: DocuSign
Published Date: Apr 24, 2018
Life science companies are experiencing a significant transformation in how they bring new products to market.
Organizations must adapt to changes in the marketplace, such as global product commercialization, specialized medicine, new regulations, new payment models, and new technology that are driving more product variety, smaller drug volumes, and shorter product life cycles.
To meet the needs of this new commercial model, life science companies must re-envision the global supply chain and evolve the tools they use to run their business. The supply chain that was designed for launching blockbuster products will not work in the future.
Today, the global supply chain relies on a manual, paper-based process centered on printing documents and sending them via overnight mail, fax, or e-mail with scanned attachments. This time-consuming and costly process is errorprone, tedious for customers and team members, and vulnerable to security and compliance risks.
Credit Union Times is the nation's leading independent source for breaking news and analysis for credit union leaders. For more than 20 years, Credit Union Times has set the standard for editorial excellence and ethical, straight-forward reporting.